GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - Chief Executive Officer
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter 2023 financial results on Friday, November
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Co
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter 2023 financial results on Wednesday, Augus
GlycoMimetics' Phase 3 study of uproleselan for acute myeloid leukemia is expected to continue until early 2024, with the FDA seeking more information on survivability rates. Insider buying and techni
Rarely, a developmental biotech comes along with new chemistry that potentially becomes curative via transplantation. Blood cancers such as AML, MM, and MDS extract a terrible toll on patients and the
GlycoMimetics, Inc. (NASDAQ:GLYC ) Q4 2022 Results Conference Call March 29, 2023 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel and Company Secretary Harout Semerjian - Chie
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on We
Independent Data Monitoring Committee interim analysis concludes that the phase 3 study, using uproleselan in combination with chemotherapy for the treatment of relapsed/refractory AML patients should

GLYC Stock: 62.47% Plummet Explanation

05:36am, Thursday, 16'th Feb 2023
The stock price of GlycoMimetics Inc (NASDAQ: GLYC) dropped by 62.47% in the most recent trading session. This is why.
Penny stocks to watch this week. The post Penny Stocks To Buy After CPI Report?
GlycoMimetics may have discovered a successful treatment for AML leukemia, currently with a 5-year survival rate of around 30%. Small research trial sizes have delivered exceptional results, with the
Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?
Here is how GlycoMimetics (GLYC) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE